Table 2.
Clinical details
| Variable (n = 21) | Value (%) |
|---|---|
| Recipient age, median (range) | 15 (1.5–43) |
| Above 18 Years (n) | 7 (33.3%) |
| Below 18 Years (n) | 14 (66.6%) |
| Donor age in years, median (range) | 39 (17–70) |
| Recipient sex | |
| Male | 14 (66.66%) |
| female | 7 (33.33%) |
| Donor sex | |
| Male | 18 (85.7%) |
| Female | 3 (14.2%) |
| Parents (Father 15, Mother 2) | 17 |
| Siblings (1 brother, 1 sister) | 2 |
| Children (both sons) | 2 |
| Sex mismatch | 8 (38.1%) |
| ABO incompatible | 10 (47.6%) |
| Disease status at transplantation, | |
| ALL | 8 (38.1%) |
| CR1 (1- MLL translocation, 1- Ph-positive all) | 2 |
| CR2 | 6 |
| AML | 10 (47.6%) |
| CR1 (Both Adverse Risk–FLT3 positive) | 2 |
| CR2 | 8 |
| CML-BC (At first CCyR–high risk) | 2 (9.5%) |
| CML-AP (At first CCyR—T315I mutation) | 1 (4.7%) |
| HLA matching status, n | |
| 5/10 | 8 (38.1%) |
| 6/10 | 6 (28.5%) |
| 7/10 | 4 (19%) |
| 8/10 | 2 (9.5%) |
| 9/10 | 1 (4.7%) |
| Conditioning regimen (n) | |
| (Disease) (n) | |
| FLU-TBI | 15 (71.4%) |
| ALL | 7 |
| AML | 5 |
| CML | 3 |
| FLU-MEL-TBI | 1 (4.7%) |
| AML | 1 |
| FLU-TREO | 2 (9.5%) |
| AML | 1 |
| ALL | 1 |
| FLU-BU-Cy | 2 (9.5%) |
| AML | 2 |
| FLU-BU | 1 (4.7%) |
| AML | 1 |
| CD 34 Cell Count (× 106/kg) median (range) | 6 (4–8.6) |
| GVHD prophylaxis (n) PTCY with MMF and CSA/TAC | 21 |
| GCSF requirement, median (range) | 11 (7–26) days |
| PRC requirement, median (range) | 4 (1–15) |
| Platelet requirement, median (range) | 16 (3–85) |
| TPN requirement, n (Median) | 16 (8 days) |
| Neutrophils engraftment, median (range) | 14 (12–23) days |
| Platelets engraftment, median (range) | 14 (12–54) days |
| CMV (Reactivation) | 15 (71.4%) |
| Fungal infection | 1 (probable) |
ABO Blood grouping system; ALL Acute lymphoblastic leukemia; AML Acute myeloid leukemia; CML-BC Chronic myeloid leukemia-Blast crisis; CML-AP Chronic myeloid leukemia-Accelerated phase CR1 Complete remission 1; CR2 Complete remission 2; HLA Human leucocyte antigen FLU Fludarabine; TBI Total body irradiation; MEL Melphalan; BU Busalfan; TREO Treosulfan Cy Cyclophosphamide; CD Cluster differentiation; GVHD Graft versus host disease; PTCY Post-transplant cyclophosphamide; CSA Cyclosporine; TAC Tacrolimus; MMF Mycophenolate mofetil; GCSF Granulocyte colony-stimulating factor; PRC Packed red cell; TPN Total parental nutrition; CMV Cytomegalovirus